AIA
RPRX icon

Arcadia Investment Advisors’s Royalty Pharma RPRX Stock Holding History

Arcadia Investment Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12
Closed -$492 – 213
2021
Q2 		$492 Buy
+12
New +$510 ﹤0.01% 224

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Arcadia Investment Advisors's RPRX Position: Q3 2021 in Review

Arcadia Investment Advisors sold out of Royalty Pharma (RPRX) in Q3 2021, closing a stake of 12 shares — an estimated $492 sold.

Arcadia Investment Advisors first reported a position in RPRX in Q2 2021 and held it in 1 quarter. The position peaked at $492 in Q2 2021. 232 funds tracked by Wall St. Rank hold RPRX as of Q3 2021.

  • Arcadia Investment Advisors reported no remaining Royalty Pharma position as of Q3 2021 after selling out during the quarter.
  • Arcadia Investment Advisors sold 12 Royalty Pharma shares in Q3 2021, an estimated $492.
  • Arcadia Investment Advisors first reported a position in Royalty Pharma in Q2 2021 and held it in 1 quarter.
  • Arcadia Investment Advisors's Royalty Pharma position peaked at $492 in Q2 2021.
  • 232 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2021.

Based on Arcadia Investment Advisors's 13F filing for Q3 2021, filed 19 Dec 2024.